Abbott Agrees to Multimillion-Dollar Settlement Following 2022 Baby Formula Factory Closure and Shortage
Abbott Laboratories has agreed to a substantial financial resolution totaling $385 million to settle claims connected to a federal investigation into contamination at its infant formula manufacturing plant in Sturgis, Michigan. As the largest baby formula production facility in the United States, the closure of the plant triggered a severe nationwide supply shortage that left parents scrambling to feed their infants in 2022.
According to reports from the Associated Press, the operational issues and subsequent shutdown prompted legal action by the United States Department of Justice. The regulatory scrutiny resulted in a widespread recall of powdered infant formulas manufactured at the facility. Major brands, including popular products like Similac, were pulled from shelves, dramatically squeezing an inventory already heavily strained by pandemic-era supply chain disruptions and household stockpiling.
The newly announced financial agreement resolves multiple legal actions, including claims brought forward by the Justice Department, lawsuits from certain relators, and actions filed by the Attorneys General of several states. Representatives for Abbott Laboratories maintained that the settlement does not constitute an admission or finding of fault or liability on the part of the company.
In statements regarding the background of the 2022 recall, Abbott emphasized that testing conducted by government regulators on unopened product samples retrieved from the homes of infants involved in the original investigations tested negative for Cronobacter sakazakii. This opportunistic bacterium can cause severe invasive infections, including sepsis or meningitis, particularly in newborns and infants. Furthermore, the company reported that no unopened and distributed containers of Abbott infant formula have ever tested positive for the pathogen.
The manufacturing crisis had sweeping consequences for public health infrastructure and federal oversight. Following the initial discovery of problems, the facility was shuttered in February 2022 when the Food and Drug Administration launched its comprehensive investigation. The closure severely restricted national nutrition supplies, forcing federal authorities to intervene.
To mitigate the crisis, the federal government took unprecedented steps. Import regulations for foreign manufacturers were temporarily eased, European formula supplies were airlifted into the country, and emergency federal authorities were invoked to prioritize domestic infant formula production. After implementing corrective actions and facility upgrades, Abbott successfully reopened the Sturgis production plant by June 2022, gradually helping stabilize the national nutrition supply chain for families across the country.
Source: News-Medical.net
